+Follow
手持一堆垃圾
No personal profile
56
Follow
5
Followers
0
Topic
0
Badge
Posts
Hot
手持一堆垃圾
2021-02-10
m
Tianyan Pharmaceutical was listed on Nasdaq today, up nearly 9% at the opening
手持一堆垃圾
2021-02-08
.mn
Sorry, the original content has been removed
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3565838986169374","uuid":"3565838986169374","gmtCreate":1602744963101,"gmtModify":1611196709373,"name":"手持一堆垃圾","pinyin":"scydljshouchiyiduilaji","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/70876ea3d18ea743551d4975c629d41a","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":56,"tweetSize":25,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.57%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.09%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":383757819,"gmtCreate":1612898793131,"gmtModify":1704875809110,"author":{"id":"3565838986169374","authorId":"3565838986169374","name":"手持一堆垃圾","avatar":"https://static.tigerbbs.com/70876ea3d18ea743551d4975c629d41a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3565838986169374","idStr":"3565838986169374"},"themes":[],"htmlText":"m","listText":"m","text":"m","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/383757819","repostId":"1194244001","repostType":4,"repost":{"id":"1194244001","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1612889675,"share":"https://ttm.financial/m/news/1194244001?lang=en_US&edition=fundamental","pubTime":"2021-02-10 00:54","market":"us","language":"zh","title":"Tianyan Pharmaceutical was listed on Nasdaq today, up nearly 9% at the opening","url":"https://stock-news.laohu8.com/highlight/detail?id=1194244001","media":"老虎资讯综合","summary":"2月9日，临床阶段生物药企天演药业正式在纳斯达克挂牌上市，开盘涨8.95%，报20.7美元，市值8.73亿美元。\n\n天演药业发行价为19美元位于价格指导区间顶端，据悉本次发行735.4万份ADS，市值","content":"<p>February 9, clinical stage biopharmaceutical companies<a href=\"https://laohu8.com/S/ADAG\">Tianyan Pharmaceutical</a>Officially listed on Nasdaq, it opened up 8.95% to US $20.7, with a market value of US $873 million.</p><p><img src=\"https://static.tigerbbs.com/62e01ad7e249639d98c7aa993a51a167\" tg-width=\"1340\" tg-height=\"833\"></p><p>The issue price of Tianyan Pharmaceutical is US $19, which is at the top of the price guidance range. It is reported that 7.354 million ADSs were issued this time, with a market value of US $801 million. Goldman Sachs, Morgan Stanley, and Jeffery are the joint lead underwriters, and China Renaissance is the deputy underwriter.</p><p>According to media reports, Tianyan Pharmaceutical has a close relationship with CRO giant WuXi AppTec. WuXi AppTec is one of the investors of Tianyan Pharmaceutical, accounting for 10.8% of the shares. Some analysts said that WuXi AppTec was the behind-the-scenes supporter of Tianyan Pharmaceutical's listing in the United States.</p><p>According to official information, Tianyan Pharmaceutical was established in 2011 and is committed to transforming the discovery and development of new antibody-based cancer immunotherapies. In the years after its establishment, Tianyan Pharmaceutical independently developed dynamic precision antibody technology, established the world's largest diverse dynamic precision antibody library (DPL Platform), and the world's first high-throughput screening platform that integrates precision computational design and experimental structure and integrates yeast and phage.</p><p>Diverse dynamic precision antibody library is the core technology patent of Tianyan Pharmaceutical. The DPL platform is powered by the combination of computational physics technology, AI and big data. It can sample a potentially unlimited number of dynamic binding interface structures generated by massive antibody amino acid sequences, and produce first-to-first antibodies with excellent biological functions and druggability. Antibodies, thereby greatly improving the efficiency of antibody drug discovery.</p><p>Based on this self-owned patented platform, Tianyan Pharmaceuticals has now developed three core products: ADG106, ADG116 and ADG126. Among them, ADG106, which is used to treat advanced solid tumors, non-Hodgkin's lymphoma or NHL, is undergoing clinical trials in China and the United States. It has been observed by data to have good anti-tumor activity and tolerability, and is most expected to be commercialized.</p><p>Another product of Tianyan Pharmaceutical, ADG126, aims to solve the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapy and expand the potential of CTLA-4 as a cancer therapeutic target. The product has been approved by the FDA and will conduct phase I clinical trials in the United States this year.</p><p>As the founder of a rising star enterprise in the field of biological antibodies, Luo Peizhi, founder of Tianyan Pharmaceutical, is quite successful in the field of medical technology. Luo Peizhi graduated from Peking University and received his doctorate from the University of Chicago. In 2000, Luo Peizhi founded a biomedical company called Abmaxis, which pioneered a three-dimensional experimental structure that does not rely on antibody antigens. It can design and optimize antibody calculation and screening methods, and provide technical services for the development of innovative drugs by many biological companies around the world. Due to its technological innovation, Abmaxis was acquired by Merck in 2006, and Luo Peizhi himself was also hired by Merck as the global biopharmaceutical research and development director.</p><p>Around 2011, Luo Peizhi decided to return to China to start a business under the influence of Li Ge, an alumnus and founder of WuXi AppTec, and soon settled the company in Suzhou, not far from Wuxi, the headquarters of WuXi AppTec. In 2014, Tianyan Pharmaceutical completed Series A financing, raising a total of US $8 million. Leading investment institutions include Pharmaceutical Kang Mingde Venture Capital Fund, Fidelity (Boston) Biotechnology Fund, etc. In 2016, Tianyan Pharmaceutical's Series B financing, WuXi AppTec continued to follow the investment, helping Tianyan Pharmaceutical raise another US $28 million. In the following two years, Tianyan Pharmaceutical successively completed the C and D rounds of financing, with WuXi AppTec behind it.</p><p>Up to now, WuXi AppTec still holds 10.8% of the shares of Tianyan Pharmaceutical as a wholly-owned subsidiary Wuxi Medical Technology Insurance Fund.</p><p>On the domestic CRO track, WuXi AppTec is undoubtedly the leader. Since 2012, WuXi AppTec has begun to invest in potential Biotech companies, investing in shares in the early stage to obtain future returns. WuXi AppTec itself has certain clinical trial services and bioanalysis capabilities. In addition to funding, it can also rely on these services to provide support for start-up companies. For example, Tianyan Pharmaceutical purchased nearly US $15 million in R&D services and quality testing services from WuXi AppTec in the two years from 2018 to 2020.</p><p>The financial report shows that in 2018, 2019 and the first nine months ended September 30, 2020, since the products were not on the market, the company's revenue came entirely from the patent income granted to the pharmaceutical company Celgene, which were US $1.511 million, US $480,000 and US $310,000 respectively. During the same period, R&D expenditures increased year by year, reaching US $16.081 million, US $16.212 million and US $23.568 million respectively.</p><p>There are no listed drugs that can generate large revenue, and continuous R&D investment also caused Tianyan Pharmaceutical's net losses in the same period to be US $14.303 million, US $16.678 million, and US $29.815 million, respectively. The basic and diluted losses per share attributable to common shareholders were respectively US $0.94, US $1.10, and US $1.89.</p><p>At present, Tianyan Pharmaceutical is also increasing investment in scientific research. The company introduced in the prospectus that Tianyan Pharmaceutical intends to use 95% of the net proceeds from this offering to advance the trial of drug candidates, of which about 26% of the funds will be used for the progress of the first and second phase trials of ADG106; 26% of the funds are for ADG126 and ADG116; 43% for the company's technology and platform development and development of preclinical drug candidates; The remaining approximately 5% is for working capital and other general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianyan Pharmaceutical was listed on Nasdaq today, up nearly 9% at the opening</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianyan Pharmaceutical was listed on Nasdaq today, up nearly 9% at the opening\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-02-10 00:54</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>February 9, clinical stage biopharmaceutical companies<a href=\"https://laohu8.com/S/ADAG\">Tianyan Pharmaceutical</a>Officially listed on Nasdaq, it opened up 8.95% to US $20.7, with a market value of US $873 million.</p><p><img src=\"https://static.tigerbbs.com/62e01ad7e249639d98c7aa993a51a167\" tg-width=\"1340\" tg-height=\"833\"></p><p>The issue price of Tianyan Pharmaceutical is US $19, which is at the top of the price guidance range. It is reported that 7.354 million ADSs were issued this time, with a market value of US $801 million. Goldman Sachs, Morgan Stanley, and Jeffery are the joint lead underwriters, and China Renaissance is the deputy underwriter.</p><p>According to media reports, Tianyan Pharmaceutical has a close relationship with CRO giant WuXi AppTec. WuXi AppTec is one of the investors of Tianyan Pharmaceutical, accounting for 10.8% of the shares. Some analysts said that WuXi AppTec was the behind-the-scenes supporter of Tianyan Pharmaceutical's listing in the United States.</p><p>According to official information, Tianyan Pharmaceutical was established in 2011 and is committed to transforming the discovery and development of new antibody-based cancer immunotherapies. In the years after its establishment, Tianyan Pharmaceutical independently developed dynamic precision antibody technology, established the world's largest diverse dynamic precision antibody library (DPL Platform), and the world's first high-throughput screening platform that integrates precision computational design and experimental structure and integrates yeast and phage.</p><p>Diverse dynamic precision antibody library is the core technology patent of Tianyan Pharmaceutical. The DPL platform is powered by the combination of computational physics technology, AI and big data. It can sample a potentially unlimited number of dynamic binding interface structures generated by massive antibody amino acid sequences, and produce first-to-first antibodies with excellent biological functions and druggability. Antibodies, thereby greatly improving the efficiency of antibody drug discovery.</p><p>Based on this self-owned patented platform, Tianyan Pharmaceuticals has now developed three core products: ADG106, ADG116 and ADG126. Among them, ADG106, which is used to treat advanced solid tumors, non-Hodgkin's lymphoma or NHL, is undergoing clinical trials in China and the United States. It has been observed by data to have good anti-tumor activity and tolerability, and is most expected to be commercialized.</p><p>Another product of Tianyan Pharmaceutical, ADG126, aims to solve the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapy and expand the potential of CTLA-4 as a cancer therapeutic target. The product has been approved by the FDA and will conduct phase I clinical trials in the United States this year.</p><p>As the founder of a rising star enterprise in the field of biological antibodies, Luo Peizhi, founder of Tianyan Pharmaceutical, is quite successful in the field of medical technology. Luo Peizhi graduated from Peking University and received his doctorate from the University of Chicago. In 2000, Luo Peizhi founded a biomedical company called Abmaxis, which pioneered a three-dimensional experimental structure that does not rely on antibody antigens. It can design and optimize antibody calculation and screening methods, and provide technical services for the development of innovative drugs by many biological companies around the world. Due to its technological innovation, Abmaxis was acquired by Merck in 2006, and Luo Peizhi himself was also hired by Merck as the global biopharmaceutical research and development director.</p><p>Around 2011, Luo Peizhi decided to return to China to start a business under the influence of Li Ge, an alumnus and founder of WuXi AppTec, and soon settled the company in Suzhou, not far from Wuxi, the headquarters of WuXi AppTec. In 2014, Tianyan Pharmaceutical completed Series A financing, raising a total of US $8 million. Leading investment institutions include Pharmaceutical Kang Mingde Venture Capital Fund, Fidelity (Boston) Biotechnology Fund, etc. In 2016, Tianyan Pharmaceutical's Series B financing, WuXi AppTec continued to follow the investment, helping Tianyan Pharmaceutical raise another US $28 million. In the following two years, Tianyan Pharmaceutical successively completed the C and D rounds of financing, with WuXi AppTec behind it.</p><p>Up to now, WuXi AppTec still holds 10.8% of the shares of Tianyan Pharmaceutical as a wholly-owned subsidiary Wuxi Medical Technology Insurance Fund.</p><p>On the domestic CRO track, WuXi AppTec is undoubtedly the leader. Since 2012, WuXi AppTec has begun to invest in potential Biotech companies, investing in shares in the early stage to obtain future returns. WuXi AppTec itself has certain clinical trial services and bioanalysis capabilities. In addition to funding, it can also rely on these services to provide support for start-up companies. For example, Tianyan Pharmaceutical purchased nearly US $15 million in R&D services and quality testing services from WuXi AppTec in the two years from 2018 to 2020.</p><p>The financial report shows that in 2018, 2019 and the first nine months ended September 30, 2020, since the products were not on the market, the company's revenue came entirely from the patent income granted to the pharmaceutical company Celgene, which were US $1.511 million, US $480,000 and US $310,000 respectively. During the same period, R&D expenditures increased year by year, reaching US $16.081 million, US $16.212 million and US $23.568 million respectively.</p><p>There are no listed drugs that can generate large revenue, and continuous R&D investment also caused Tianyan Pharmaceutical's net losses in the same period to be US $14.303 million, US $16.678 million, and US $29.815 million, respectively. The basic and diluted losses per share attributable to common shareholders were respectively US $0.94, US $1.10, and US $1.89.</p><p>At present, Tianyan Pharmaceutical is also increasing investment in scientific research. The company introduced in the prospectus that Tianyan Pharmaceutical intends to use 95% of the net proceeds from this offering to advance the trial of drug candidates, of which about 26% of the funds will be used for the progress of the first and second phase trials of ADG106; 26% of the funds are for ADG126 and ADG116; 43% for the company's technology and platform development and development of preclinical drug candidates; The remaining approximately 5% is for working capital and other general corporate purposes.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/b19a2d6f03716b3591e388e25f762874","relate_stocks":{"ADAG":"天演药业"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194244001","content_text":"2月9日，临床阶段生物药企天演药业正式在纳斯达克挂牌上市，开盘涨8.95%，报20.7美元，市值8.73亿美元。\n\n天演药业发行价为19美元位于价格指导区间顶端，据悉本次发行735.4万份ADS，市值达到8.01亿美元。高盛、摩根士丹利、Jeffery为联席主承销商，华兴资本为副承销商。\n根据媒体报道，天演药业与CRO巨头药明康德的关系密切，药明康德系天演药业投资方之一，股份占比10.8%。有分析称，天演药业赴美上市，幕后助力者正是药明康德。\n根据官方信息，天演药业成立于2011年，致力于改变基于抗体的新型癌症免疫疗法的发现和开发。成立后的几年间，天演药业自主开发了动态精准抗体技术，建立起全球最大的多样性动态精准抗体库（DPL Platform），以及全球首个融合了精准计算设计与实验构造并集酵母和噬菌体于一体的高通量筛选平台。\n多样性动态精准抗体库是天演药业的核心技术专利。该DPL平台由计算物理技术与AI和大数据相结合提供支持，可对由海量抗体氨基酸序列产生的潜在无限数量的动态结合界面结构进行采样，生产同时具备优异生物学功能与成药性的先到抗体，从而大幅提高抗体药物发现的效率。\n基于这一自有专利平台，天演药物现开发了三个核心产品：ADG106、ADG116和ADG126。其中用于治疗晚期实体瘤、非霍奇金淋巴瘤或NHL的ADG106正在中美两国进行临床试验，已被数据观察到具有良好的抗肿瘤活性与耐受性，最有望实现商业化。\n天演药业的另一产品ADG126，旨在解决与现有批准的CTLA-4免疫肿瘤疗法的MOA相关的毒性和功效问题，并扩大CTLA-4作为癌症治疗靶标的潜力。该产品现已由FDA获批，将于今年在美开展Ⅰ期临床试验。\n作为生物抗体领域的新星企业的创始人，天演药业创始人罗培志在医药科技领域颇为成功。罗培志毕业于北京大学，在美国芝加哥大学获得博士学位。2000年，罗培志创立了一家名为Abmaxis的生物医药公司，开创了不依赖抗体抗原的三维实验结构，可以设计和优化抗体的计算及筛选方法，为全球多家生物公司的创新药开发提供技术服务。因其技术创新，Abmaxis在2006年被默沙东收购，罗培志本人也受聘到默沙东担任全球生物制药研发主任。\n2011年左右，罗培志在校友、药明康德创始人李革的影响下，决定回国创业，很快将公司落户在离与药明康德总部无锡不远的苏州。2014年，天演药业完成A轮融资，共募集资金800万美元。领投机构包括药康明德创投基金、富达（波士顿）生物科技基金等。2016年天演药业的B轮融资，药明康德继续跟投，帮助天演药业再度融资2800万美元。此后的两年中，天演药业陆续完成了C轮、D轮融资，背后都有药明康德的身影。\n截至目前，药明康德仍以全资子公司无锡市医药科技保险基金的身份持有天演药业10.8%的股份。\n在国内CRO赛道上，药明康德无疑是领跑者。从2012年起，药明康德就开始布局投资具有潜力的Biotech公司，前期投资入股，获取未来收益。药明康德本身便具有一定的临床试验服务和生物分析等能力，在资金之外，其也可以凭借这些服务为初创公司提供支持。比如天演药业，在2018年至2020年两年里，共向药明康德购买了近1500万美元的研发服务与质量检测服务。\n财报显示，2018年、2019年及截至2020年9月30日的前9个月，由于产品均未上市，公司收入完全来自向制药公司新基授权专利所得，分别为151.1万美元、48万美元及31万美元。同一时期，研发支出在逐年上升，分别为1608.1万美元、1621.2万美元和2356.8万美元。\n没有能产生大额收入的上市药物，持续不断的研发投入也造成天演药业同期净亏损分别为1430.3万美元、1667.8万美元、2981.5万美元，归属于普通股股东的基本和摊薄每股亏损分别为0.94美元、1.10美元和1.89美元。\n目前，天演药业也在加大科研上的投入。公司在招股书中介绍，天演药业打算利用此次发行的净收益95%用于推进候选药物的试验，其中约26%的资金用于ADG106第一阶段试验和第二阶段试验的进展；26%的资金用于ADG126和ADG116；43%用于公司的技术和平台开发以及临床前候选药物的开发；剩余约5%用于营运资金和其他一般公司用途。","news_type":1,"symbols_score_info":{"ADAG":0.9}},"isVote":1,"tweetType":1,"viewCount":1488,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":389552807,"gmtCreate":1612790940909,"gmtModify":1704874223547,"author":{"id":"3565838986169374","authorId":"3565838986169374","name":"手持一堆垃圾","avatar":"https://static.tigerbbs.com/70876ea3d18ea743551d4975c629d41a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3565838986169374","idStr":"3565838986169374"},"themes":[],"htmlText":".mn","listText":".mn","text":".mn","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/389552807","repostId":"1181758367","repostType":4,"isVote":1,"tweetType":1,"viewCount":1939,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":383757819,"gmtCreate":1612898793131,"gmtModify":1704875809110,"author":{"id":"3565838986169374","authorId":"3565838986169374","name":"手持一堆垃圾","avatar":"https://static.tigerbbs.com/70876ea3d18ea743551d4975c629d41a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3565838986169374","idStr":"3565838986169374"},"themes":[],"htmlText":"m","listText":"m","text":"m","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/383757819","repostId":"1194244001","repostType":4,"repost":{"id":"1194244001","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1612889675,"share":"https://ttm.financial/m/news/1194244001?lang=en_US&edition=fundamental","pubTime":"2021-02-10 00:54","market":"us","language":"zh","title":"Tianyan Pharmaceutical was listed on Nasdaq today, up nearly 9% at the opening","url":"https://stock-news.laohu8.com/highlight/detail?id=1194244001","media":"老虎资讯综合","summary":"2月9日，临床阶段生物药企天演药业正式在纳斯达克挂牌上市，开盘涨8.95%，报20.7美元，市值8.73亿美元。\n\n天演药业发行价为19美元位于价格指导区间顶端，据悉本次发行735.4万份ADS，市值","content":"<p>February 9, clinical stage biopharmaceutical companies<a href=\"https://laohu8.com/S/ADAG\">Tianyan Pharmaceutical</a>Officially listed on Nasdaq, it opened up 8.95% to US $20.7, with a market value of US $873 million.</p><p><img src=\"https://static.tigerbbs.com/62e01ad7e249639d98c7aa993a51a167\" tg-width=\"1340\" tg-height=\"833\"></p><p>The issue price of Tianyan Pharmaceutical is US $19, which is at the top of the price guidance range. It is reported that 7.354 million ADSs were issued this time, with a market value of US $801 million. Goldman Sachs, Morgan Stanley, and Jeffery are the joint lead underwriters, and China Renaissance is the deputy underwriter.</p><p>According to media reports, Tianyan Pharmaceutical has a close relationship with CRO giant WuXi AppTec. WuXi AppTec is one of the investors of Tianyan Pharmaceutical, accounting for 10.8% of the shares. Some analysts said that WuXi AppTec was the behind-the-scenes supporter of Tianyan Pharmaceutical's listing in the United States.</p><p>According to official information, Tianyan Pharmaceutical was established in 2011 and is committed to transforming the discovery and development of new antibody-based cancer immunotherapies. In the years after its establishment, Tianyan Pharmaceutical independently developed dynamic precision antibody technology, established the world's largest diverse dynamic precision antibody library (DPL Platform), and the world's first high-throughput screening platform that integrates precision computational design and experimental structure and integrates yeast and phage.</p><p>Diverse dynamic precision antibody library is the core technology patent of Tianyan Pharmaceutical. The DPL platform is powered by the combination of computational physics technology, AI and big data. It can sample a potentially unlimited number of dynamic binding interface structures generated by massive antibody amino acid sequences, and produce first-to-first antibodies with excellent biological functions and druggability. Antibodies, thereby greatly improving the efficiency of antibody drug discovery.</p><p>Based on this self-owned patented platform, Tianyan Pharmaceuticals has now developed three core products: ADG106, ADG116 and ADG126. Among them, ADG106, which is used to treat advanced solid tumors, non-Hodgkin's lymphoma or NHL, is undergoing clinical trials in China and the United States. It has been observed by data to have good anti-tumor activity and tolerability, and is most expected to be commercialized.</p><p>Another product of Tianyan Pharmaceutical, ADG126, aims to solve the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapy and expand the potential of CTLA-4 as a cancer therapeutic target. The product has been approved by the FDA and will conduct phase I clinical trials in the United States this year.</p><p>As the founder of a rising star enterprise in the field of biological antibodies, Luo Peizhi, founder of Tianyan Pharmaceutical, is quite successful in the field of medical technology. Luo Peizhi graduated from Peking University and received his doctorate from the University of Chicago. In 2000, Luo Peizhi founded a biomedical company called Abmaxis, which pioneered a three-dimensional experimental structure that does not rely on antibody antigens. It can design and optimize antibody calculation and screening methods, and provide technical services for the development of innovative drugs by many biological companies around the world. Due to its technological innovation, Abmaxis was acquired by Merck in 2006, and Luo Peizhi himself was also hired by Merck as the global biopharmaceutical research and development director.</p><p>Around 2011, Luo Peizhi decided to return to China to start a business under the influence of Li Ge, an alumnus and founder of WuXi AppTec, and soon settled the company in Suzhou, not far from Wuxi, the headquarters of WuXi AppTec. In 2014, Tianyan Pharmaceutical completed Series A financing, raising a total of US $8 million. Leading investment institutions include Pharmaceutical Kang Mingde Venture Capital Fund, Fidelity (Boston) Biotechnology Fund, etc. In 2016, Tianyan Pharmaceutical's Series B financing, WuXi AppTec continued to follow the investment, helping Tianyan Pharmaceutical raise another US $28 million. In the following two years, Tianyan Pharmaceutical successively completed the C and D rounds of financing, with WuXi AppTec behind it.</p><p>Up to now, WuXi AppTec still holds 10.8% of the shares of Tianyan Pharmaceutical as a wholly-owned subsidiary Wuxi Medical Technology Insurance Fund.</p><p>On the domestic CRO track, WuXi AppTec is undoubtedly the leader. Since 2012, WuXi AppTec has begun to invest in potential Biotech companies, investing in shares in the early stage to obtain future returns. WuXi AppTec itself has certain clinical trial services and bioanalysis capabilities. In addition to funding, it can also rely on these services to provide support for start-up companies. For example, Tianyan Pharmaceutical purchased nearly US $15 million in R&D services and quality testing services from WuXi AppTec in the two years from 2018 to 2020.</p><p>The financial report shows that in 2018, 2019 and the first nine months ended September 30, 2020, since the products were not on the market, the company's revenue came entirely from the patent income granted to the pharmaceutical company Celgene, which were US $1.511 million, US $480,000 and US $310,000 respectively. During the same period, R&D expenditures increased year by year, reaching US $16.081 million, US $16.212 million and US $23.568 million respectively.</p><p>There are no listed drugs that can generate large revenue, and continuous R&D investment also caused Tianyan Pharmaceutical's net losses in the same period to be US $14.303 million, US $16.678 million, and US $29.815 million, respectively. The basic and diluted losses per share attributable to common shareholders were respectively US $0.94, US $1.10, and US $1.89.</p><p>At present, Tianyan Pharmaceutical is also increasing investment in scientific research. The company introduced in the prospectus that Tianyan Pharmaceutical intends to use 95% of the net proceeds from this offering to advance the trial of drug candidates, of which about 26% of the funds will be used for the progress of the first and second phase trials of ADG106; 26% of the funds are for ADG126 and ADG116; 43% for the company's technology and platform development and development of preclinical drug candidates; The remaining approximately 5% is for working capital and other general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianyan Pharmaceutical was listed on Nasdaq today, up nearly 9% at the opening</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianyan Pharmaceutical was listed on Nasdaq today, up nearly 9% at the opening\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-02-10 00:54</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>February 9, clinical stage biopharmaceutical companies<a href=\"https://laohu8.com/S/ADAG\">Tianyan Pharmaceutical</a>Officially listed on Nasdaq, it opened up 8.95% to US $20.7, with a market value of US $873 million.</p><p><img src=\"https://static.tigerbbs.com/62e01ad7e249639d98c7aa993a51a167\" tg-width=\"1340\" tg-height=\"833\"></p><p>The issue price of Tianyan Pharmaceutical is US $19, which is at the top of the price guidance range. It is reported that 7.354 million ADSs were issued this time, with a market value of US $801 million. Goldman Sachs, Morgan Stanley, and Jeffery are the joint lead underwriters, and China Renaissance is the deputy underwriter.</p><p>According to media reports, Tianyan Pharmaceutical has a close relationship with CRO giant WuXi AppTec. WuXi AppTec is one of the investors of Tianyan Pharmaceutical, accounting for 10.8% of the shares. Some analysts said that WuXi AppTec was the behind-the-scenes supporter of Tianyan Pharmaceutical's listing in the United States.</p><p>According to official information, Tianyan Pharmaceutical was established in 2011 and is committed to transforming the discovery and development of new antibody-based cancer immunotherapies. In the years after its establishment, Tianyan Pharmaceutical independently developed dynamic precision antibody technology, established the world's largest diverse dynamic precision antibody library (DPL Platform), and the world's first high-throughput screening platform that integrates precision computational design and experimental structure and integrates yeast and phage.</p><p>Diverse dynamic precision antibody library is the core technology patent of Tianyan Pharmaceutical. The DPL platform is powered by the combination of computational physics technology, AI and big data. It can sample a potentially unlimited number of dynamic binding interface structures generated by massive antibody amino acid sequences, and produce first-to-first antibodies with excellent biological functions and druggability. Antibodies, thereby greatly improving the efficiency of antibody drug discovery.</p><p>Based on this self-owned patented platform, Tianyan Pharmaceuticals has now developed three core products: ADG106, ADG116 and ADG126. Among them, ADG106, which is used to treat advanced solid tumors, non-Hodgkin's lymphoma or NHL, is undergoing clinical trials in China and the United States. It has been observed by data to have good anti-tumor activity and tolerability, and is most expected to be commercialized.</p><p>Another product of Tianyan Pharmaceutical, ADG126, aims to solve the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapy and expand the potential of CTLA-4 as a cancer therapeutic target. The product has been approved by the FDA and will conduct phase I clinical trials in the United States this year.</p><p>As the founder of a rising star enterprise in the field of biological antibodies, Luo Peizhi, founder of Tianyan Pharmaceutical, is quite successful in the field of medical technology. Luo Peizhi graduated from Peking University and received his doctorate from the University of Chicago. In 2000, Luo Peizhi founded a biomedical company called Abmaxis, which pioneered a three-dimensional experimental structure that does not rely on antibody antigens. It can design and optimize antibody calculation and screening methods, and provide technical services for the development of innovative drugs by many biological companies around the world. Due to its technological innovation, Abmaxis was acquired by Merck in 2006, and Luo Peizhi himself was also hired by Merck as the global biopharmaceutical research and development director.</p><p>Around 2011, Luo Peizhi decided to return to China to start a business under the influence of Li Ge, an alumnus and founder of WuXi AppTec, and soon settled the company in Suzhou, not far from Wuxi, the headquarters of WuXi AppTec. In 2014, Tianyan Pharmaceutical completed Series A financing, raising a total of US $8 million. Leading investment institutions include Pharmaceutical Kang Mingde Venture Capital Fund, Fidelity (Boston) Biotechnology Fund, etc. In 2016, Tianyan Pharmaceutical's Series B financing, WuXi AppTec continued to follow the investment, helping Tianyan Pharmaceutical raise another US $28 million. In the following two years, Tianyan Pharmaceutical successively completed the C and D rounds of financing, with WuXi AppTec behind it.</p><p>Up to now, WuXi AppTec still holds 10.8% of the shares of Tianyan Pharmaceutical as a wholly-owned subsidiary Wuxi Medical Technology Insurance Fund.</p><p>On the domestic CRO track, WuXi AppTec is undoubtedly the leader. Since 2012, WuXi AppTec has begun to invest in potential Biotech companies, investing in shares in the early stage to obtain future returns. WuXi AppTec itself has certain clinical trial services and bioanalysis capabilities. In addition to funding, it can also rely on these services to provide support for start-up companies. For example, Tianyan Pharmaceutical purchased nearly US $15 million in R&D services and quality testing services from WuXi AppTec in the two years from 2018 to 2020.</p><p>The financial report shows that in 2018, 2019 and the first nine months ended September 30, 2020, since the products were not on the market, the company's revenue came entirely from the patent income granted to the pharmaceutical company Celgene, which were US $1.511 million, US $480,000 and US $310,000 respectively. During the same period, R&D expenditures increased year by year, reaching US $16.081 million, US $16.212 million and US $23.568 million respectively.</p><p>There are no listed drugs that can generate large revenue, and continuous R&D investment also caused Tianyan Pharmaceutical's net losses in the same period to be US $14.303 million, US $16.678 million, and US $29.815 million, respectively. The basic and diluted losses per share attributable to common shareholders were respectively US $0.94, US $1.10, and US $1.89.</p><p>At present, Tianyan Pharmaceutical is also increasing investment in scientific research. The company introduced in the prospectus that Tianyan Pharmaceutical intends to use 95% of the net proceeds from this offering to advance the trial of drug candidates, of which about 26% of the funds will be used for the progress of the first and second phase trials of ADG106; 26% of the funds are for ADG126 and ADG116; 43% for the company's technology and platform development and development of preclinical drug candidates; The remaining approximately 5% is for working capital and other general corporate purposes.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/b19a2d6f03716b3591e388e25f762874","relate_stocks":{"ADAG":"天演药业"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194244001","content_text":"2月9日，临床阶段生物药企天演药业正式在纳斯达克挂牌上市，开盘涨8.95%，报20.7美元，市值8.73亿美元。\n\n天演药业发行价为19美元位于价格指导区间顶端，据悉本次发行735.4万份ADS，市值达到8.01亿美元。高盛、摩根士丹利、Jeffery为联席主承销商，华兴资本为副承销商。\n根据媒体报道，天演药业与CRO巨头药明康德的关系密切，药明康德系天演药业投资方之一，股份占比10.8%。有分析称，天演药业赴美上市，幕后助力者正是药明康德。\n根据官方信息，天演药业成立于2011年，致力于改变基于抗体的新型癌症免疫疗法的发现和开发。成立后的几年间，天演药业自主开发了动态精准抗体技术，建立起全球最大的多样性动态精准抗体库（DPL Platform），以及全球首个融合了精准计算设计与实验构造并集酵母和噬菌体于一体的高通量筛选平台。\n多样性动态精准抗体库是天演药业的核心技术专利。该DPL平台由计算物理技术与AI和大数据相结合提供支持，可对由海量抗体氨基酸序列产生的潜在无限数量的动态结合界面结构进行采样，生产同时具备优异生物学功能与成药性的先到抗体，从而大幅提高抗体药物发现的效率。\n基于这一自有专利平台，天演药物现开发了三个核心产品：ADG106、ADG116和ADG126。其中用于治疗晚期实体瘤、非霍奇金淋巴瘤或NHL的ADG106正在中美两国进行临床试验，已被数据观察到具有良好的抗肿瘤活性与耐受性，最有望实现商业化。\n天演药业的另一产品ADG126，旨在解决与现有批准的CTLA-4免疫肿瘤疗法的MOA相关的毒性和功效问题，并扩大CTLA-4作为癌症治疗靶标的潜力。该产品现已由FDA获批，将于今年在美开展Ⅰ期临床试验。\n作为生物抗体领域的新星企业的创始人，天演药业创始人罗培志在医药科技领域颇为成功。罗培志毕业于北京大学，在美国芝加哥大学获得博士学位。2000年，罗培志创立了一家名为Abmaxis的生物医药公司，开创了不依赖抗体抗原的三维实验结构，可以设计和优化抗体的计算及筛选方法，为全球多家生物公司的创新药开发提供技术服务。因其技术创新，Abmaxis在2006年被默沙东收购，罗培志本人也受聘到默沙东担任全球生物制药研发主任。\n2011年左右，罗培志在校友、药明康德创始人李革的影响下，决定回国创业，很快将公司落户在离与药明康德总部无锡不远的苏州。2014年，天演药业完成A轮融资，共募集资金800万美元。领投机构包括药康明德创投基金、富达（波士顿）生物科技基金等。2016年天演药业的B轮融资，药明康德继续跟投，帮助天演药业再度融资2800万美元。此后的两年中，天演药业陆续完成了C轮、D轮融资，背后都有药明康德的身影。\n截至目前，药明康德仍以全资子公司无锡市医药科技保险基金的身份持有天演药业10.8%的股份。\n在国内CRO赛道上，药明康德无疑是领跑者。从2012年起，药明康德就开始布局投资具有潜力的Biotech公司，前期投资入股，获取未来收益。药明康德本身便具有一定的临床试验服务和生物分析等能力，在资金之外，其也可以凭借这些服务为初创公司提供支持。比如天演药业，在2018年至2020年两年里，共向药明康德购买了近1500万美元的研发服务与质量检测服务。\n财报显示，2018年、2019年及截至2020年9月30日的前9个月，由于产品均未上市，公司收入完全来自向制药公司新基授权专利所得，分别为151.1万美元、48万美元及31万美元。同一时期，研发支出在逐年上升，分别为1608.1万美元、1621.2万美元和2356.8万美元。\n没有能产生大额收入的上市药物，持续不断的研发投入也造成天演药业同期净亏损分别为1430.3万美元、1667.8万美元、2981.5万美元，归属于普通股股东的基本和摊薄每股亏损分别为0.94美元、1.10美元和1.89美元。\n目前，天演药业也在加大科研上的投入。公司在招股书中介绍，天演药业打算利用此次发行的净收益95%用于推进候选药物的试验，其中约26%的资金用于ADG106第一阶段试验和第二阶段试验的进展；26%的资金用于ADG126和ADG116；43%用于公司的技术和平台开发以及临床前候选药物的开发；剩余约5%用于营运资金和其他一般公司用途。","news_type":1,"symbols_score_info":{"ADAG":0.9}},"isVote":1,"tweetType":1,"viewCount":1488,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":389552807,"gmtCreate":1612790940909,"gmtModify":1704874223547,"author":{"id":"3565838986169374","authorId":"3565838986169374","name":"手持一堆垃圾","avatar":"https://static.tigerbbs.com/70876ea3d18ea743551d4975c629d41a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3565838986169374","idStr":"3565838986169374"},"themes":[],"htmlText":".mn","listText":".mn","text":".mn","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/389552807","repostId":"1181758367","repostType":4,"isVote":1,"tweetType":1,"viewCount":1939,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
